Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | ABL2 |
| Gene Name: | ABL2 |
| Protein Full Name: | Tyrosine-protein kinase ABL2 |
| Alias: | Abelson-related gene; ABLL; ARG; EC 2.7.10.2; Kinase Arg; Tyrosine kinase ARG; V-abl Abelson murine leukemia viral oncogene 2; V-abl Abelson murine leukemia viral oncogene homolog 2 |
| Mass (Da): | 128343 |
| Number AA: | 1182 |
| UniProt ID: | P42684, D1MPS6 |
| Locus ID: | 27 |
| COSMIC ID: | ABL2 |
| Gene location on chromosome: | 1q25 |
| Cancer protein type: | OP/TSP |
| Effect of cancer mutation on protein: | GAIN |
| Effect of active protein on cancer: | PROMOTES (wild-type likely inhibits) |
| Number of cancer specimens: | 1073 |
| Percent of cancer specimens with mutations: | 1.3047530289 |
| Deregulated in translocations: | ETV6 |
| Normal role description: | ABL2 of the Albelson family nonreceptor tyrosine kinases. It shares many functions with ABL1 which includes cytoskeleton remodelling through phosphorylation of enzymes responsible for cytoskeleton rearrangements for signalling, adhesion, and movement as well as microtuble subunits, TUBA1 and TUBB. It contains F-actin binding region to bundle and regulate actin cytoskeletal structure. It contains autocatalytical activity and the ability to phosphorylate its inhitor to regulate itself. It is often found as a fusion gene with ETV6 in acute non lymphocytic leukemia. |